Jade Biosciences, Inc. (JBIO)
NASDAQ: JBIO · Real-Time Price · USD
21.04
+0.20 (0.96%)
At close: May 29, 2026, 4:00 PM EDT
21.68
+0.64 (3.06%)
After-hours: May 29, 2026, 6:11 PM EDT
Jade Biosciences Employees
Jade Biosciences had 55 employees as of December 31, 2025. The number of employees increased by 25 or 83.33% compared to the previous year.
Employees
55
Change
25
Growth
83.33%
Revenue / Employee
n/a
Profits / Employee
-$1,729,036
Market Cap
1.04B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 55 | 25 | 83.33% |
| Dec 31, 2024 | 30 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MannKind | 592 |
| Maravai LifeSciences Holdings | 416 |
| Pharming Group | 407 |
| EyePoint | 214 |
| Zenas BioPharma | 167 |
| DBV Technologies | 161 |
| Olema Pharmaceuticals | 137 |
| Inventiva | 77 |
JBIO News
- 5 hours ago - Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy - GlobeNewsWire
- 3 days ago - Jade Biosciences announces first participant dosed in JADE201 Phase 1 trial - TheFly
- 3 days ago - Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody - GlobeNewsWire
- 3 days ago - Jade Biosciences announces first participant dosed in Phase 2 Juniper trial - TheFly
- 3 days ago - Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy - GlobeNewsWire
- 18 days ago - Jade Biosciences price target raised to $34 from $24 at Wedbush - TheFly
- 18 days ago - Jade Biosciences price target raised to $32 from $23 at Guggenheim - TheFly
- 22 days ago - Jade Biosciences files $600M mixed securities shelf - TheFly